drugset / Trial / NCT05437601
Effect of Astaxanthin in Moderate to Severe Knee Osteoarthritis
RandomizedParallel-groupDouble-blindTreatment
Summary
This study will be 8 weeks randomized, double-blind, placebo-controlled trail to assess the effect of astaxanthin in 80 moderate to severe knee osteoarthritis patients. Participants will be assessed at baseline and after 8 weeks of intervention. Subjects will be randomized to receive either astaxanthin 12 mg capsule daily or placebo capsule identical to astaxanthin daily for 8 weeks. Evaluation of pain, stiffness and improvement of physical function will be measured by WOMAC index before and after intervention. Inflammatory markers serum IL-6 and hsCRP will be measured before and after intervention. Astaxanthin related adverse events will be identified. Study outcome will establish safety and efficacy of astaxanthin in knee osteoarthritis.
Timeline
- Start
- 2022-07-31
- Primary completion
- 2022-12-19
- Completion
- 2022-12-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Astaxanthin | Small molecule | 12 mg | Oral |